128 related articles for article (PubMed ID: 37401372)
1. Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice.
Huang J; Chen J
J Liposome Res; 2024 Mar; 34(1):97-112. PubMed ID: 37401372
[TBL] [Abstract][Full Text] [Related]
2. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes.
Qhattal HS; Hye T; Alali A; Liu X
ACS Nano; 2014 Jun; 8(6):5423-40. PubMed ID: 24806526
[TBL] [Abstract][Full Text] [Related]
4. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
5. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
[TBL] [Abstract][Full Text] [Related]
6. Assessment of hyaluronic acid-modified imatinib mesylate cubosomes through CD44 targeted drug delivery in NDEA-induced hepatic carcinoma.
Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh P; Tabassum H; Alka ; Singh S; Guleria A; Saraf SA
Int J Pharm; 2022 Jun; 622():121848. PubMed ID: 35613653
[TBL] [Abstract][Full Text] [Related]
7. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
8. Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an
Negi LM; Talegaonkar S; Jaggi M; Verma AK
J Drug Target; 2019 Feb; 27(2):183-192. PubMed ID: 29972336
[TBL] [Abstract][Full Text] [Related]
9. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
10. In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery.
Xu H; Ji H; Li Z; Qiao W; Wang C; Tang J
Int J Nanomedicine; 2021; 16():1221-1229. PubMed ID: 33628019
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
13. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth and metastasis of breast cancer by targeted delivery of 17-hydroxy-jolkinolide B via hyaluronic acid-coated liposomes.
Liu D; Zhang Q; Wang J; Guan S; Cai D; Liu J
Carbohydr Polym; 2021 Apr; 257():117572. PubMed ID: 33541631
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
16. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
17. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
[TBL] [Abstract][Full Text] [Related]
18. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII.
Lu L; Ding Y; Zhang Y; Ho RJ; Zhao Y; Zhang T; Guo C
Int J Nanomedicine; 2018; 13():1927-1944. PubMed ID: 29636610
[TBL] [Abstract][Full Text] [Related]
19. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
[TBL] [Abstract][Full Text] [Related]
20. HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma.
Zhang X; Chen H; Zhang Y; Huang Q; Feng J; Xing H; Fu X; Yan X; Zhang Y; Xu Q; Liang J
Int J Nanomedicine; 2022; 17():5137-5151. PubMed ID: 36345507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
